

University of Groningen

**Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma**

Tete, Sarah M.; Bijl, Marc; Sahota, Surinder S.; Bos, Nicolaas

*Published in:*  
Frontiers in Immunology

*DOI:*  
[10.3389/fimmu.2014.00257](https://doi.org/10.3389/fimmu.2014.00257)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2014

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Tete, S. M., Bijl, M., Sahota, S. S., & Bos, N. (2014). Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. *Frontiers in Immunology*, 5, [257]. <https://doi.org/10.3389/fimmu.2014.00257>

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



# Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma

Sarah M. Tete<sup>1,2</sup>, Marc Bijl<sup>3</sup>, Surinder S. Sahota<sup>2†</sup> and Nicolaas A. Bos<sup>1\*†</sup>

<sup>1</sup> Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

<sup>2</sup> Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK

<sup>3</sup> Department of Internal Medicine and Rheumatology, Martini Hospital, Groningen, Netherlands

## Edited by:

Harry W. Schroeder, University of Alabama at Birmingham, USA

## Reviewed by:

Biao Zheng, Baylor College of Medicine, USA; University of Texas Medical School, USA

Stamatis-Nick Liossis, University of Patras Medical School, Greece

## \*Correspondence:

Nicolaas A. Bos, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, PO Box 30.001, Groningen 9700 RB, Netherlands

e-mail: n.a.bos@umcg.nl

<sup>†</sup> Surinder S. Sahota and Nicolaas A. Bos – Joint Senior Authors.

The plasma cell proliferative disorders monoclonal gammopathy of undetermined significance (MGUS) and malignant multiple myeloma (MM) are characterized by an accumulation of transformed clonal plasma cells in the bone marrow and production of monoclonal immunoglobulin. They typically affect an older population, with median age of diagnosis of approximately 70 years. In both disorders, there is an increased risk of infection due to the immunosuppressive effects of disease and conjointly of therapy in MM, and response to vaccination to counter infection is compromised. The underlying factors in a weakened immune response in MGUS and MM are as yet not fully understood. A confounding factor is the onset of normal aging, which quantitatively and qualitatively hampers humoral immunity to affect response to infection and vaccination. In this review, we examine the status of immune alterations in MGUS and MM and set these against normal aging immune responses. We focus primarily on quantitative and functional aspects of B-cell immunity. Furthermore, we review the current knowledge relating to susceptibility to infectious disease in MGUS and MM, and how efficacy of conventional vaccination is affected by proliferative disease-related and therapy-related factors.

**Keywords: MGUS, multiple myeloma, infections, immune defects, vaccination**

## INTRODUCTION

Understanding immunosenescence has now emerged as a priority to counter immunological susceptibility to disease in normal aging. Evidence is revealing that the B-cell compartment and the associated immune synapse in the aging immune response underlie an increased susceptibility to infections and decreased response to vaccination (1). In age-related immunosenescence, onset of hematological disease may further ameliorate immune capacity, and a combination of these factors has as yet received little attention. To address this, we focus on a non-malignant B-cell clonal expansion in late age, on monoclonal gammopathy of undetermined significance (MGUS) where plasma cells accrue to <10% of the bone marrow. This condition provides a unique model to understand how immune susceptibility is impaired in aging by disease. The model extends and acquires a further urgency when it is recognized that MGUS almost invariably precedes transformation to malignant multiple myeloma (MM) (2), in which humoral immune capacity deteriorates further. Currently however, how the efficacy of B-cell response to generate protective humoral immunity diminishes in these disease states is largely undefined. Understanding this will be crucial for successful intervention with vaccination to counter infections in MGUS and MM, and reduce the associated morbidity and mortality. Consequently, this review examines B-cell dysfunction in monoclonal disease spanning MGUS to MM.

Monoclonal gammopathy of undetermined significance incidence increases with advancing age. It is usually diagnosed by chance and is characterized by the presence of a serum monoclonal immunoglobulin (M-protein) (<30 g/L). MGUS is present in 3% of people over 50 years and up to 5% over 70 years (3, 4). A newly described subtype of MGUS in which the secreted M-protein lacks IgH to skew the free light-chain-(FLC)-ratio, defined as light-chain MGUS, occurs in approximately 0.8% of the population aged over 50 years to establish an overall prevalence of MGUS to 4.2% in persons aged 50 years and older (5, 6). MGUS requires clinical vigilance, to establish onset of MM. Seminal observations by Landgren and co-workers established that MM patients invariably had a previously recognized M-protein as MGUS during a nationwide population-based cohort screen (2). These paradigm shifting findings were substantiated by Weiss et al. by detection of a monoclonal gammopathy in prediagnostic sera in 90% of 30 myeloma patients (7). As yet, it is difficult to accurately predict the subset that will progress in MGUS after initial diagnosed and this remains an important area of investigation (3, 8). Interestingly, light-chain MGUS is also a precursor of light-chain MM, which comprises 20% of all MM cases; this association has important implications for understanding the nature of the “feeder” cell for plasma cell malignancy (9–11). Furthermore, progression rates differ, as IgH MGUS transforms at the rate of 1% per year but light-chain MGUS has a progression rate of 0.3% per year, which is significantly lower (4, 6, 12). Of particular relevance to the need

to understand immune capacity in disease, it has been established that loss of immune control, among other factors is implicated in malignant transformation from asymptomatic disease to MM (13–16). The immune status in MGUS and MM therefore needs to be fully understood, for therapeutic intervention to prevent progression and to counter susceptibility to infection.

In clinical diagnosis, MGUS lack the overt clinical CRAB symptoms that define MM: hypercalcemia, renal insufficiency, anemia, and bone lesions (11). In the MGUS–MM transition, key stages of high clinical relevance can also be defined, as asymptomatic smoldering MM (SMM), plateau phase disease, and active disease. SMM fulfills the diagnostic criteria for MM, with serum M-protein  $\geq 30$  g/L and/or bone marrow clonal plasma cells  $\geq 10\%$  however without clinical CRAB symptoms or end organ damage that dictate therapeutic intervention. Although SMM is an asymptomatic precursor of symptomatic MM, it differs from MGUS as the risk of progression to MM is much higher (10% per year) as compared to MGUS (1% per year) (11, 17). This 10-fold increased risk alone suggests that SMM differs biologically to MGUS. The SMM–MM transition is at present a focal area of research, driven by the need to understand the molecular and cellular basis of full blown clonal transformation. Although recent therapies and better supportive care have improved the survival of MM, it remains largely incurable (median survival 4–5 years) (18, 19).

## THE RISK AND SPECTRUM OF INFECTIONS IN MGUS AND MM

It is important when assessing susceptibility to infection in MGUS and MM that healthy controls are age-matched, to obviate an aging immunosenescence and this has generally been the case in reported studies. The risk of bacteremia in MGUS is increased ~2-fold as compared to healthy controls, with an increased susceptibility to a broad range of bacterial infections that include pneumonia, osteomyelitis, septicemia, pyelonephritis, endocarditis, and meningitis (20). In viral infections, MGUS patients have an increased risk of developing influenza and herpes zoster infections at a risk comparable to that for bacterial infections (20). High monoclonal protein at diagnosis associates with higher risks of infection: MGUS patients with monoclonal protein  $>25$  g/L at diagnosis have the highest risk of infections, and the risk is still significantly increased in MGUS patients with monoclonal protein  $<5$  g/L as compared to healthy controls (20). M-protein levels are most likely a surrogate for clonal expansion and concomitant immunosuppression. MGUS patients have an increased mortality due to bacterial infections, with a hazard ratio of 3:4 (21).

Depressed antibody titers to a number of common infectious pathogens have been found in several conditions associated with presence of an M-protein. Serum IgG antibody levels directed to 24 different microorganisms were evaluated in Waldenström's macroglobulinemia, a lymphoma subtype secreting monoclonal IgM paraprotein, and in MGUS and MM (22). Significantly depressed antibody levels to a number of antigens, particularly staphylococcal, moraxella, pneumococcal, varicella zoster, and also for fungal antigens such as *Candida* and *Aspergillus* were observed in MGUS (22). However, a significant decrease in antibody titers was also observed in WM and MM, revealing that humoral immune response to most of these pathogens is suppressed. There

appears to be an increased susceptibility to infections in MGUS that worsens as disease progresses to MM, as indicated by antibody titers. The duration of antibody response and their protective value however varies between different pathogens, with some specific antibody levels that remain stable over a long time. The variability in humoral response to different pathogens indicates a requirement to carefully dissect responses to individual infectious agents in MGUS and MM.

There is clear evidence of immune dysfunction in MM that leads to vulnerability to infection, a leading cause of morbidity and mortality. Lymphocytopenia (23), hypogammaglobulinemia (24), and granulocytopenia secondary to bone marrow infiltration and therapy (25) are factors that are consistently found to increase the susceptibility of MM patients to infections. In a study of 3107 newly diagnosed MM patients in the UK Medical Research Council Trial from 1980 to 2002, infections caused 135 deaths (45%) of all deaths, occurring within 60 days of diagnosis and with two-thirds of these being attributed to pneumonia (26). The risk of infection is highest in the first 3 months and decreases with response to treatment, revealing a direct causative links as tumor burden is reduced. The most frequent infections are bacteremia and pneumonia caused by *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Escherichia coli* (27–29). These microorganisms predominate in the early stages of disease and in plateau phase, but in the terminal phase of the disease the spectrum of causative microorganisms widens (29, 30). Recurrent bacterial infections at presentation meet the diagnostic criteria for symptomatic MM (11).

In addition to intrinsic disease-derived factors, the type of therapy used in symptomatic MM also plays a role in susceptibility to infection. Chemotherapy can disrupt the mucosal barriers thereby increasing the risk of infections (31). Induction therapy for MM has changed recently and the traditional oral melphalan and prednisone (MP) as well as vincristine–adriamycin–dexamethasone (VAD) combinations have been replaced by dexamethasone, thalidomide, bortezomib, and lenalidomide-based regimens (32, 33). Although well- and better-tolerated, the use of novel therapies results in an increased risk of opportunistic infections as well as the shift in the spectrum of infections in MM. Novel therapeutic agents increase the risk of viral infections; bortezomib therapy for instance, increases the risks of herpes zoster reactivation in the first few months of treatment due to the immunosuppressive effects on T cells (34, 35). Dexamethasone use is associated with a greater risk of infections, and associates with depressed cell-mediated immunity against cytomegalovirus and varicella-zoster virus (36, 37). Notably, high-dose dexamethasone is associated with higher rate of infections (18%) in comparison to low-dose dexamethasone (9%), as shown in a randomized controlled trial of newly diagnosed MM (38). The lack of immune reconstitution due to poor disease response to therapy leaves patients with an on-going immune deficiency that perpetuates their risk of infections. It is also conceivable that infections may have a potential role in enhancing the survival of myeloma cells but this has as yet not been fully addressed. Infections are frequent in MM and microorganisms are known to induce B-cell activation through Toll-like receptors (TLR). MM cells express TLR and TLR-specific ligands have been shown to induce cell proliferation

and prevent apoptosis of human myeloma cell lines (39, 40). This further exemplifies an unwanted tumor adaptation to exploit local niche characteristics.

## NORMAL AGE-ASSOCIATED CHANGES IN HUMORAL RESPONSE

The immune status of patients with MGUS or MM has to be seen in the light of the aging immune system. Qualitative as well as quantitative changes in the humoral immune response occur with late age. The B-cell repertoire and maturation response are critical in mediating protection against infection (41). Antigen response in B cells may occur with T-cell help for T-cell-dependent (TD) maturation, or can result in T-cell-independent (TI) antibody formation. Both can generate B-cell memory, although the TD pathway is largely responsible for long-term memory by generating plasma cells that home to and reside in the bone marrow; both pathways are a pre-requisite in vaccination aimed at inducing protective antibody titers (42).

A number of studies have shown a decline in total CD19+ B cells frequencies with age, and shifts in specific B-cell subset populations (43–45). A decrease in naïve B cells together with memory and plasma cells has been reported (46). In B-cell memory, the IgM component (CD19+ IgM+ IgD+ CD27+) plays an important role in response to bacterial infections and declines with age (47). There are also age-related decreases in the IgD– CD27+ switched memory B-cell pool (43, 47, 48). Furthermore, a decrease in the number and percentage of circulating plasma cells is seen with age (49). Newly arising subpopulations termed “age-associated B cells,” defined as CD21low, CD23low, CD11c+ that seem to be more responsive to TLR7 and TLR9 ligands than direct B-cell receptor (BCR) stimulation have been described (50). Antigen-specific B cells populations are altered with the changes evident as decreased antibody responses to influenza and pneumococcal vaccination (47, 51). In mechanistic insights, key observations suggest an intrinsic defect in deletional class switch recombination (CSR) due to decreased expression of activation-induced cytidine deaminase (AID) with age (43, 52). AID is a pre-requisite for both TD and TI B-cell responses. As a result, weak and low affinity antibody responses are elicited. Induction of sustainable B-cell responses is therefore a challenge in the elderly.

Changes in B-cell subpopulations impact on the available repertoire in aging and this has been mapped by spectratyping and gene sequencing studies looking at immunoglobulin heavy-chain variable region complementarity-determining region 3 (CDR3) use. These studies reveal a collapse in BCR diversity due to B-cell oligoclonal expansions that occur with age (53). Oligoclonality is also associated with poor health status (frailty) (54). This loss of diversity will clearly impair the B-cell response to new antigenic challenge.

Senescence of humoral immunity impairs immunogenicity and efficacy of vaccination with a number of studies providing evidence that age impacts on response (55–57). Immune response to influenza vaccination declines with age. In young adults, vaccination is 70–90% effective against influenza (protective titers against two or three of the influenza viral strains) especially when the vaccine matches the circulating strains (58, 59). However, in

the elderly population, influenza vaccination is only 60% effective, although it may be up to 80% effective in the prevention of serious influenza complications (60, 61). Other than the inferior antibody response generated in the elderly in comparison to that of young adults (56, 62), a decreased anti-viral cell-mediated response is also apparent (56).

Infections caused by encapsulated extracellular bacteria such as *Streptococcus pneumonia* and *Haemophilus influenza* type B (Hib) are an important health issue in aging. The bacterial polysaccharide capsule *per se* provides a challenge for vaccine design to counter invasive disease. Capsular polysaccharides as antigens do not generate a memory response (63) and the antibody response to polysaccharide vaccine is short-lived (64). However, polysaccharide vaccines are more immunogenic when conjugated to a carrier protein (65, 66), as a result of the switch from a TI to a TD response. A 23-valent pneumococcal polysaccharide vaccine is currently licensed for use in the elderly since they become infected with a broad range of serotypes. Nonetheless, the effectiveness of the 23-valent pneumococcal polysaccharide vaccine in the elderly remains controversial. In a study by Rubins and colleagues, only 20% of the elderly (>65 years) had a twofold increase in specific antibody following vaccination. Moreover, they did not respond to the most prevalent serotypes causing invasive disease (67). An earlier study of elderly males showed a response to all seven measured serotypes that was comparable to that of young adults (68). Other studies have shown that vaccination reduces the incidence of hospitalization and mortality in the elderly (69–71) and is effective in 45% vaccinated individuals in preventing *Streptococcus pneumonia* infection (70). Nasopharyngeal carriage of *Streptococcus pneumonia* has the highest prevalence in infants and naturally induced anti-polysaccharide IgG prevents carriage in the adult (72). However, in the elderly naturally acquired anti-polysaccharide IgG and IgM decrease with age (73), and additional protection is not conferred by simultaneously administering pneumococcal and influenza vaccinations in the elderly (74, 75). Of the six serotypes of encapsulated *Haemophilus influenza*, type b is the most virulent, causing invasive diseases such as meningitis, septicemia, and pneumonia. A number of Hib-conjugate vaccines are licensed for use and the estimate of protective anti-Hib polysaccharide antibodies, 0.15–1 µg/mL (76, 77), are based on the assumption that protection from invasive disease is solely mediated by antibodies, with negligible contributions of cell-mediated immunity. In the elderly, Hib polysaccharide conjugate vaccine-induced specific IgG antibodies are of comparable affinity as those generated in young adults (78), and Hib polysaccharide conjugate vaccination elicits a strong and rapid response in the elderly that results in protective titers (79).

In addition to diminution of antibody responses, an increase in reactivity toward autologous antigens that leads to autoantibody production in the elderly is indicative of a wider malaise in humoral responses, suggesting loss of tolerogenic control and check-points (80–82).

Alterations in T-cell immunity that can contribute to the development of infections also occur with aging; these thymic atrophy-related changes in T-cell proportions as well as function changes have been reviewed elsewhere (83–85).



## IMMUNE DEFECTS IN MGUS AND MM

### B-CELL FUNCTION

B-cell dysfunction is less profound in MGUS than in MM. This can be tracked by studies on uninvolved polyclonal serum immunoglobulins as hypogammaglobulinemia, which reflects the influence of the tumor clone on the spectrum of immunoglobulin production. Hypogammaglobulinemia occurs at a lower frequency in MGUS (25–28%) (3, 86, 87), is more frequent in SMM (45–83%) (17, 88, 89) and is often associated with MM (25, 90). The frequency of hypogammaglobulinemia associates with disease progression and the reciprocal depression of uninvolved immunoglobulins is a prognostic factor for progression to MM (17, 88, 89, 91, 92). These findings support the concept that progressive immunodeficiency is a feature of disease progression in MM.

### B-cell enumeration

Circulating CD19+ B cells in MGUS are numerically normal or decreased in comparison to age-matched HCs (93–95). In MM, the significant depression of circulating CD19+ B-cell frequencies correlates inversely with stage of disease, and coupled with defective cell-mediated immunity in late stage disease contributes to the increased risk of infection (25).

Plasma cells are the long-term depots of antibody generating cells in the normal BM. MGUS plasma cells display phenotypic heterogeneity as compared to their normal counterparts. Based on the expression of CD19 and CD56, two distinct subpopulations of plasma cells can be seen. The first population of plasma cells is polyclonal and has an identical phenotype to normal BM plasma cells, observed as CD19+ CD56– CD38+ CD138+. A second population of abnormal plasma cells is characterized by restricted intracytoplasmic light-chain expression and lack of expression of CD19 and/or CD56 [Ref. (96) – this paper does not look at CD45]. These abnormal plasma cells can be detected at low frequencies (limit of detection 0.01% of leukocytes) by using combined immunophenotyping and clonality assessment (97, 98). Abnormal MGUS clonal plasma cells have the same phenotype as MM clonal plasma cells (99). There is a progressive replacement of normal BM polyclonal plasma cells by clonal (tumor) plasma cells as disease advances from MGUS to MM (100, 101). Normal plasma cells have been found to make up to 86% of total BM plasma cells in MGUS and 0–32% in MM (96). The number of residual polyclonal plasma cells in BM can therefore distinguish between MGUS and MM with 98% MGUS patients having >3% normal plasma cells and only 1.5% MM having >3% normal plasma cells. From these observations alone, it is apparent that normal (polyclonal) long-lived plasma cell memory deteriorates markedly in MM.

Not only is the increase in aberrant clonal plasma cell populations likely to impact on normal plasma cell compartment, but also associates with egress into the circulation. The circulating abnormal plasma cells have been found to be a significant predictor of progression in MGUS (91, 100, 102, 103), and clonal plasma cells can also be detected in the peripheral blood of SMM as well as MM (104–106). Circulating abnormal plasma cells can be detected in up to 20% of MGUS patients (102, 103) and up to 80% MM (107, 108). The increase in circulating plasma cells parallels their increase in bone marrow (101).

### T-CELL FUNCTION

Several studies have sought to evaluate defects in T-cell frequencies and function broadly in MGUS and myeloma. At present, there is limited evidence for both decreased antigen-specific T-cell responses and less so for T-dependent B-cell antigen-specific responses.

Significant aberrations in T-cell count and function have been described in MGUS and MM. A decrease in CD4+/CD8+ ratio due to increased CD8+ T cells in the bone marrow and circulation has been reported in both conditions (95), or due to lower CD4+ T-cell numbers (102), whereas others have shown that the MGUS CD4+/CD8+ ratio and absolute numbers do not differ significantly from healthy controls (109). Within the CD4+ T-cell compartment in MM, selective loss of the naïve CD4+ CD45R+ subset has been reported (110).

Th1/Th2 cytokine balance regulates the immune response. Th1/Th2 polarization depends on the local cytokine concentrations that induce differentiation of naïve T lymphocytes to either Th1 cells, which promote cell-mediated immunity, or Th2 cells, which promote antibody-mediated immunity (111, 112). In many hematological malignancies, however, the balance is changed (113, 114). In MGUS, the balance seems comparable to healthy individuals (115), whereas in MM, there is an imbalanced Th1/Th2 ratio that results in a defective Th1 response (115). This defective Th1 response correlates with disease stage and is related to elevated levels of IL-6 and increased numbers of IL-6+CD3+ T cells. Local concentrations of IL-12 that induce differentiation of naïve T lymphocytes to a Th1 phenotype, however, are compromised by IL-10 and fail to induce polarization of activated T lymphocytes *in vivo* in MM (115).

To examine T-cell response to infectious agent antigens, Maecker et al. characterized the *in vitro* CD8+ T-cell response in HLA-A\*0201+ MM patients and healthy individuals to influenza A and Epstein–Barr virus-derived immunodominant epitopes using major histocompatibility complex (MHC)/peptide tetramers (116). Following *in vitro* stimulation, 67% healthy individuals showed an increased frequency of antigen-specific T cells for both antigens while in myeloma the magnitude of the response was reduced, with <30% reacting to both viral antigens (116). These findings need to be expanded to examine antigen-specific T-cell capacity *in vivo* to vaccination to a wider spectrum of infection-related antigens. Chemotherapy aggravates the immunodeficient state of myeloma patients, resulting in significant reductions in CD4+ as well as specific reductions in CD4+ CD45RO+ cells as compared to untreated myeloma; this decrease is strongly associated with opportunistic infections (25).

The induction of effector T-cells in response to active vaccination (e.g., to counter infection) will be influenced by functional regulatory T-cells (Tregs). Treg cells play an important role in modulating immune response, maintaining immune homeostasis, and suppressing excessive immune responses where any imbalances lead to impaired immune functions. Several subsets of Tregs have been identified; naturally occurring CD4+CD25+FoxP3+ Tregs (nTregs) that are generated in the thymus, and peripherally inducible Tregs that include type I T-regulatory (Tr1) that constitutively express IL-10 and Th3 CD4+ Tregs that produce TGF- $\beta$  (117–119). Furthermore, CD8+ as well as double-negative Treg

(DN Treg) cells have also been described (120, 121). Tregs can regulate the effector Th1 and Th2 responses by production of soluble cytokines IL-10 and transforming growth factor- $\beta$  (TGF- $\beta$ ) and/or contact dependent mechanisms (122, 123).

There is significant discrepancy in the literature regarding the frequency of Treg cells and their function in MGUS and MM that is probably related to the differences in techniques and markers used to identify these cells. A report by Prabhala et al. showed that the frequency of CD4+FoxP3+ Tregs in MGUS and MM is reduced and they were functionally impaired as the Tregs had significantly reduced ability to suppress T-cell proliferation (124). In contrast, Beyer et al. found a significantly increased frequency of CD4+CD25<sup>hi</sup>FoxP3+ Tregs in MGUS as well as treated and untreated myeloma. Using allogenic T cell stimulation, they showed that these cells also maintained their functionality as they inhibited proliferation and IFN- $\gamma$  production (125). Other studies confirmed that CD4+CD25+FoxP3+ Treg cells were increased and this increase correlated with disease activity in MM (126, 127). A marked decrease in DN Tregs has also been reported in MM (126). A reduced frequency or compromised Treg activity on the other hand may be deleterious to the host, as this results in dysfunctional T cell responses and increased risk of infections (128).

#### DC FUNCTION

Dendritic cells (DCs) as professional antigen presenting cells play a central role in recruiting host adaptive immunity. Using blood dendritic cell antigen (BDCA) labeled DCs, plasmacytoid DC (pDC) (BDCA-2+) and myeloid DC1 (mDC1) (BDCA-1+) cells were found to be suppressed in MGUS and further reduced as the disease progressed in MM (94). The reduced number of circulating mDCs and pDCs in MM are characterized by a lower expression of HLA-DR, CD40, and CD80, in addition to an impaired induction of T cell proliferation and cytokine stimulation (129, 130). The functional defects result from IL-6 inhibiting the growth of CD34+ DC progenitors and switching development and maturation of CD34+ cells from DC toward monocytic cells with phagocytic activity but with no antigen-presentation capacity (129). Enumeration of high potency CMRF44+ CD14- CD19- DCs in MM in peripheral blood approached relatively normal numbers, expressing expected levels of CD80 and CD86. They did however exhibit functional defects with reduced capacity to up-regulate CD80 and CD86 expression after CD40L and IL-2 stimuli. This stimulatory defect may result from tumor-derived TGF- $\beta$ 1 and IL-10 that down-regulate CD80 (131). Potentially, this can be abrogated by anti-TGF- $\beta$ 1 and IL-10 antibodies. IL-12 and IFN- $\gamma$  can also neutralize the failure to stimulate CD80 upregulation (132). As in other immune compartments, specific therapeutic agents can impact on DC function: bortezomib, a major drug in MM, significantly impairs the immunostimulatory capacity of mDCs (133, 134). An additional consideration is that pDCs have been strikingly shown to interact with MM cells to induce tumor cell growth and survival (135). Nonetheless, DCs remain a major target for immunotherapeutic intervention in MM (136).

While DC considerations in MGUS and MM have relevance to understanding many aspects of immune response to vaccination against infection, in relation to T-dependent B-cell responses in

germinal canthers, it is the follicular DC specialized subset that is important in generating B-cell memory, coupled with T<sub>FH</sub> cells (137). As yet, disease impact on these secondary lymphoid organ immune cell interactions has not been investigated in MGUS or MM.

#### NK CELL FUNCTION

Natural killer cells have a role in immune response to viral infection (138, 139), and interface with adaptive immunity. They also play an important role in initial immune response to tumor cells, but as yet there is no concrete evidence for a surveillance and anti-tumor role for NK cells in response to the premalignant clone in MGUS. Increased numbers of NK cells have been described in MGUS, in newly diagnosed MM and in low tumor burden MM (140–142). NK cell function is intact in the setting of MGUS and newly diagnosed MM. However, NK cytotoxicity against MM decreases as disease progresses (140, 141, 143). The downregulation of NK cell activating receptors NKG2D, NKp30, and CD244 in MGUS and MM in the bone marrow niche but not in the circulation suggests a possible mechanism of immune escape of the tumor clone (144). MHC I molecules are critical determinants of NK cell activity. The expression levels of MHC class I polypeptide-related chain A (MICA), a soluble ligand of NKG2D is increased on plasma cells in MGUS and is strongly expressed in advancing disease in MM (145). However, the soluble NKG2D ligand, MICA, shed by MM cells as disease progresses, as a result of the upregulation of ERp5 (146) down-regulates NKG2D on effector NK cells. NKG2D levels are diminished in MM with MICA shedding, which contributes to immune suppression (146, 147). Normal to increased lytic activity of peripheral blood, NK cells have been described in MGUS but in MM with MICA shedding NK activity is decreased (146). The immunomodulatory agents thalidomide and lenalidomide have been reported to enhance NK cell cytotoxicity against MM cells (148), highlighting an aspect of current therapy that appears to potentiate immune capacity in disease, and increased NK cells are also seen in the peripheral blood of patients that respond to therapy (149).

#### THE IMMUNOSUPPRESSIVE MICROENVIRONMENT OF MM

A number of factors induce the immunosuppressive microenvironment that promotes tumor survival in MM and simultaneously induces immune dysfunction. Immunosuppressive factors include increased levels of IL-6, IL-10, IL-15, and TGF- $\beta$  (150). They reduce anti-tumor immunity by suppressing NK cell cytotoxicity, and IL-10 and IL-6 have been implicated in DC dysfunction, as discussed above (115, 129). TGF- $\beta$  also has a central role in inhibiting IL-2-induced T cell proliferation (151). Vascular endothelial growth factor (VEGF) is an important cytokine in the MM microenvironment as it not only promotes the secretion of IL-6 but also the growth and migration of MM cells (152). Specific tumor adaptations in MM cells mediate immunosuppression. Cyclooxygenase-2 (COX-2) overexpression by MM cells, which correlates with poor outcome, is also implicated in suppressing macrophage-mediated or T-cell-mediated tumor killing (153). For effective therapy against infection, a combinational approach is required: tailored vaccination together with strategies to combat the immunosuppressive MM microenvironment.

## HUMORAL IMMUNE RESPONSE TO INFLUENZA, PNEUMOCOCCAL, AND Hib VACCINATION IN MM VACCINATION FOLLOWING CHEMOTHERAPY

Patients with MM undergoing chemotherapy are at an increased risk of contracting influenza, but it remains uncertain as to whether these patients are able to mount sufficient immune response to benefit from vaccination. Previous studies have shown heterogeneous responses to influenza vaccination in myeloma (discussed below). A comparison of studies of immune response to influenza vaccination is limited by differences in read-outs used to interpret response to vaccination. Most studies measure antibody levels by the hemagglutinin inhibition (HI) test, and responses are defined as  $\geq 2.5$ -fold rise HI after vaccination. Seroconversion is defined as a  $\geq 4$ -fold rise in titer and seroprotection as a titer of at least 1:40 (154, 155). Vaccination against influenza in MM is still a matter of clinical uncertainty, in part as knowledge about the protective efficacy against clinical disease (influenza) itself is limited, especially in aging. Controlled studies in MM evaluating influenza vaccination with clinical endpoints (contracting influenza and severity of infection) are lacking. Despite this clinical uncertainty, influenza vaccination is recommended in MM patients.

In a study of MM patients the results of influenza vaccination were disappointing as only 10% achieved protection against two viral strains and 19% developed protective antibody titers to all three strains in the vaccine (156). Comparable observations were noted in another study of 70 patients with hematological malignancies of which 16 were MM cases, and of the 70 only 4 responded, but none were MM, to achieve seroprotection to all 3 viral strains (157). Moreover, two doses of influenza vaccine failed to improve antibody response to influenza vaccination in patients with hematological malignancy undergoing therapy or with recently discontinued therapy as the response rate did not increase following a second booster dose of the vaccine (158, 159). Overall, the booster influenza vaccination strategy failed to increase the antibody response in immunocompromised patients.

Notwithstanding these observations, patients with hematological malignancies, even under treatment, can mount protective immune responses against influenza vaccination. Indeed, in a study of 34 patients with chronic lymphoproliferative disorders and MM, some receiving therapy, response rates were comparable to healthy controls (160). More than 60% achieved seroprotective responses to all three viral strains, and of the six patients with MM, three developed seroprotection to all three viral strains. However, these studies were limited by the low number of subjects and by patients on diverse therapy with varying dosage intensity. This precluded detection of a relation between response to vaccination and disease state and stage and also the relation between vaccination response and treatment.

Initial studies in the early 80s that utilized the 14-valent pneumococcal capsular polysaccharide vaccine showed that MM patients responded poorly to immunization. The antibody concentrations to 12 of the 14 polysaccharides in the vaccine were simultaneously measured by radioimmunoassay. Radiolabeled polysaccharides were incubated with sera and the resulting antigen-antibody complexes were precipitated and quantified with a scintillation counter as nanograms of antibody protein

nitrogen/milliliter (161). The interpretation of an adequate response to the 14-valent pneumococcal vaccine was variable since the antibody concentrations needed for protection were difficult to define (162). Low levels of antibody were reported to pneumococcal capsular polysaccharides before and after vaccination in MM patients, significantly lower than those in healthy controls (163–165). Lazarus et al. showed that in MM patients before vaccination, the grand geometric mean antibody concentrations for all serotypes combined was 91 ng/mL, which is less than their presumed protective level of 215 ng antibody nitrogen/mL (165). Following vaccination, the grand geometric mean antibody concentration remained significantly lower in MM than in healthy controls (91 versus 820 ng antibody nitrogen/mL). Thirty percent of the patients had an antibody response that might be protective for half of the vaccine serotypes. Geometric mean titers  $> 215$  ng antibody nitrogen/mL developed only for serotypes 3, 18C, and 23F. Similarly, Schmid et al. observed antibody titers  $> 200$  ng antibody nitrogen/mL only for serotypes 1, 4, 18C, and 23F in myeloma patients (163). A study of 42 MM patients reported immunization responses that were inferior to those of HCs and the low anti-pneumococcal titers correlated with risk of serious infection (166). MM patients with IgG M-protein were shown to have lower antibody titers compared to those with IgA or Bence Jones MM. In line with these observations, Schmid et al. also showed that patients with IgA MM consistently responded with higher antibody titers than IgG MM and had higher increases in levels of antibodies after pneumococcal vaccination (163). These studies indicate that generation of antibodies to pneumococcal capsular polysaccharide vaccination is impaired. This may be because pneumococcal polysaccharides are particularly weakly immunogenic in the immune suppressed state of these patients. Polysaccharide vaccines are more immunogenic when conjugated to a carrier protein (discussed above). However, MM patients elicit sub-protective to protective antibody responses to Hib polysaccharide conjugate vaccination: Nix and colleagues reported that 45% of MM had protective titers in a study by Robertson and colleagues (156, 167). A more recent study utilizing the currently used 23-valent pneumococcal vaccine reported that the response to pneumococcal vaccination was again disappointing, with 56% having a fourfold rise in titer and 39% achieving protective antibody titers 4–6 weeks after vaccination (156). These responses to adjuvant in conjugated vaccine flag up deficiencies in pre-requisite Th responses in MM.

## TRANSPLANTATION

Ablative chemotherapy followed by bone marrow transplantation generally results in an acute immunosuppression in both arms of innate and adaptive immune system that lasts for several months, resulting in a protracted functional recovery. B-cell reconstitution after hematopoietic stem cell transplantation (HSCT) is slow, with B cells reaching normal levels 4–8 months post-transplant (168, 169). Re-population of T cells is also prolonged (170), appearing as abnormal subpopulations that show an inverted CD4/CD8 ratio (171, 172). The prolonged and severe immune suppression following autologous and allogeneic stem cell transplantation not only compromises immunity and pose a risk for infection but also results in poor responses to vaccination (173–175). Impaired

**Table 1 | Results of studies of the efficacy of influenza, pneumococcal, and Hib vaccination in multiple myeloma.**

Vaccine	Study	Study design number of patients	Myeloma treatment	Measure of efficacy	Response	Conclusion
<b>Influenza</b>	Robertson et al. (156)	MM ( <i>n</i> = 48)	IFN $\alpha$ /chemotherapy/ high-dose MP/total body radiation + autologous stem cell transplantation 6 months before	GMT, titers $\geq 1: 40$	Poor response. 19% achieved seroprotection and 59% had no seroprotective levels to any of the three strains	Poor responses and patients are susceptible to infections with influenza
	Rapezzi et al. (160)	MM ( <i>n</i> = 6) CLL ( <i>n</i> = 13) NHL ( <i>n</i> = 7) HD ( <i>n</i> = 8)	MP + prednisone/ MP + prednisone + VAD	GMT, titers $\geq 1: 40$	Seroprotection rates achieved by more than 60%. Of the patients, three of six MM achieved seroprotection rates	Vaccination is well-tolerated and safe in CLPD and MM
	Stadtmauer et al. (181)	MM ( <i>n</i> = 21)	High-dose MP + autologous stem cell transplantation	GMT, $\geq 4$ -fold rise in titers	Primed subjects had significantly higher GMT at all times 73% of primed subjects had seroconversion to any of the three vaccine strains and only 30% of unprimed subjects	Transfer of influenza-primed autologous T cells after transplantation improves subsequent vaccine responses
<b>Pneumococcal</b>	Lazarus et al. (165)	MM ( <i>n</i> = 13)	BCNU + adriamycin/ MP + prednisone/ cyclophosphamide/ BCNU + prednisone + cyclophosphamide/ MP + adriamycin + vincristine	GMT, $\geq 2$ -fold rise in titer	Poor response. 30% achieved protective response to six or more serotypes	Antibody response is depressed. Advisable to vaccinate patients as response was highly variable
	Schmid et al. (163)	MM ( <i>n</i> = 37) HC ( <i>n</i> = 10)	MP + prednisone/ vincristine + cyclophosphamide + prednisone (and doxorubicin/MP), or another combination of three or more/no chemotherapy for at least 3 months before vaccination	GMT $\geq 2$ -fold rise in titers	At least twofold increase in titers to at least eight antigens in 43% compared to 100% HC. Poorer response in those receiving multi-agent ( $\geq 3$ ) chemotherapy	Very low antibody titers before and after vaccination but as response was heterogeneous vaccination can be offered
	Hargreaves et al. (166)	MM ( <i>n</i> = 41) HC ( <i>n</i> = 62)	MP/MP + adriamycin + BCNU + cyclophosphamide/ vincristine + cyclophosphamide + MP + prednisone/ vincristine + BCNU + adriamycin + prednisone/ vincristine + adriamycin + dexamethasone/ vincristine + adriamycin + MP + prednisone	GMT, $\geq 2$ -fold rise in titer	Poor response 45% achieved protective titers	Poor response associated with increased risk of septicemia

(Continued)



**Table 1 | Continued**

Vaccine	Study	Study design number of patients	Myeloma treatment	Measure of efficacy	Response	Conclusion
	Robertson et al. (156)	MM ( <i>n</i> = 48)	IFN $\alpha$ /chemotherapy/high-dose MP/total body radiation + autologous stem cell transplantation 6 months before	GMT titers $\geq 1:640$	39% Achieved protective titers	Poor responses, likely to be poorly sustained. Repeat vaccination is desirable
	Rapoport et al. (180)	MM ( <i>n</i> = 42)	High-dose MP + autologous stem cell transplant	GMT	60% of pre-transplant vaccination+ post-transplant T cell infusion recipients achieved protective titers. 18% of post-transplant vaccine & pre-transplant+ late T cell infusion recipients achieved protective titers	Early adoptive T cell transfer followed by post-transplant booster immunization improves immunodeficiency. Pre-transplant vaccination regime superior to post-transplant vaccination regime
	Hinge et al. (177)	MM ( <i>n</i> = 60)	High-dose MP + autologous stem cell transplantation	GMT titers $\geq 1:40$	Poor response. 33% responded	Reasonable to vaccinate patients with disease control (responding well to induction therapy) as they have higher response rate
<b>Hib</b>	Robertson et al. (156)	MM ( <i>n</i> = 46)	IFN $\alpha$ /chemotherapy/high-dose MP/total body radiation + autologous stem cell transplantation 6 months before	$\geq 1.02 \mu\text{g/L}$	75% protective titers and 41% had a $\geq 4$ -fold increase in titers	Specific immunity comparable to HC.
	Nix et al. (167)	MM ( <i>n</i> = 20) Chronic renal failure ( <i>n</i> = 59) Diabetes mellitus ( <i>n</i> = 30) HC ( <i>n</i> = 32)	Intermittent chemotherapy	$> 0.15 \mu\text{g/mL}$	45% MM achieved titers that correlate to natural protection in comparison to 97% HC	Lack of protective immunity against Hib in MM. Increased risk of invasive disease is a rationale for immunization

CLPD, chronic lymphoproliferative disorders; HC, healthy controls; HD, Hodgkin disease; MP, mephalan; NHL, non-Hodgkin lymphoma; VAD, vincristine–adriamycin–dexamethasone.

antibody responses to influenza have been demonstrated in this setting (159, 176), however, a longer transplant to vaccination interval is associated with better serological responses. Similarly, poor responses to pneumococcal vaccination prior to transplant (177) as well as vaccination after transplant have been reported (173, 178, 179).

In a randomized Phase 1/2 study in advanced MM undergoing high-dose mephalan and autologous stem cell transplantation (ASCT), post-transplant conjugate pneumococcal vaccination resulted in no or low antibody responses and did not increase after booster vaccination (180). However, vaccination before transplant together with the adoptive transfer of T-cells early after transplant followed by booster vaccination resulted in

robust and sustained antibody response as well as accelerated T-cell recovery (180). This achieved protective titers against four serotypes (6B, 14, 19F, and 23F) in 60% of cohort as compared to 18% when there was no vaccination. In another study of MM, autologous T cell transfer resulted in poor or no influenza vaccine responses unless the patient had received influenza vaccination prior to autologous T-cell collection (181). Clearly, the priming of the autologous T cells by pre-transplant vaccination most likely enhances antigen-specific antibody induction following transfer.

These studies demonstrate that a T-cell adoptive transfer can accelerate the numerical and functional recovery of CD4+ and CD8+ T-cells that may provide help in restoring humoral immunity in MM. Strategies to enhance lymphocyte recovery and

function (both B- and T-cell) in a transplant-associated therapeutic intervention could further improve outcome in achieving protective serological and cellular immunity to infectious agents in MM.

A detailed summary of the many strategies that have been assessed to date in vaccination against infection in MM is compiled in **Table 1**.

## CONCLUSION AND FUTURE DIRECTIONS

Immunosenescence in aging compounds immune function in MGUS and MM, which incrementally deteriorates as disease progresses to symptomatic phase. Focusing on humoral immunity, as this is a pre-requisite to counter infection in these disease settings, it is evident that a complex array of factors underlies a diminution of immune capacity. This is manifest as both numerical imbalances in B-cell and T-cell populations, and in impaired lymphocyte functionality; the immunological synapse and cross-talk between these two key immune players is not fully defined yet in MGUS or MM, and remains a key area for further investigation. Clonal expansions in MGUS and MM directly compete with niche space for long-term memory of infection, affecting polyclonal normal plasma cells in the bone marrow. Direct immunosuppression by tumor cells, including via cytokine imbalance and other mechanisms such as aberrant ligand expression to block NK cell activity, further affect the capacity of the immune system to mount effective challenge to infection, or to vaccination aimed at enhancing immunity to both viral and bacterial agents. Because of the morbidity and mortality that follow infection in MM, clinical therapy still aims at vaccinating against specific bacterial threats. Mounting effective immunity to capsular polysaccharide infection-related antigens for instance, has as yet not been optimized although linking antigen to T-cell recruiting adjuvant is a notable advance. The complications generated directly by therapeutic drugs that weaken the immune response must be understood further, to select the best strategy to restore anti-infection immunity in MM. Conversely, use of immunomodulatory drugs in MM will need further investigation in how to best harness their pro-immune function during vaccination against infection. Exploiting transplantation in therapy by prior vaccination to educate T-cells to enhance humoral response to vaccination is indicative of the types of strategy that can be utilized to counter infection. It is also highly likely that current advances in understanding how aging in the normal healthy population affects immune responses will be exploited in developing the best strategies to institute immunity against infection in MGUS and MM.

## REFERENCES

- Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. *Clin Infect Dis* (2000) **30**:931–3. doi:10.1086/313792
- Landgren O, Kyle RA, Pfeiffer RM, Katzmman JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. *Blood* (2009) **113**:5412–7. doi:10.1182/blood-2008-12-194241
- Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. *N Engl J Med* (2006) **354**:1362–9. doi:10.1056/NEJMoa054494
- Blade J, Rosinol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. *Leukemia* (2008) **22**:1651–7. doi:10.1038/leu.2008.203
- Eisele L, Durig J, Huttman A, Duhrsen U, Assert R, Bokhof B, et al. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. *Ann Hematol* (2012) **91**:243–8. doi:10.1007/s00277-011-1293-1
- Dispenzieri A, Katzmman JA, Kyle RA, Larson DR, Melton LJ III, Colby CL, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. *Lancet* (2010) **375**:1721–8. doi:10.1016/S0140-6736(10)60482-5
- Weiss B, Abadie J, Verma P, Howard R, Kuehl W. A monoclonal gammopathy precedes multiple myeloma in most patients. *Blood* (2009) **113**:5418–22. doi:10.1182/blood-2008-12-195008
- Rajkumar SV, Kyle RA, Therneau TM, Melton LJ III, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. *Blood* (2005) **106**:812–7. doi:10.1182/blood-2005-03-1038
- Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, et al. B-cell clones as early markers for chronic lymphocytic leukemia. *Mayo Clin Proc* (2009) **360**:659–67. doi:10.1056/NEJMoa0806122
- Pfeiffer S, Perez-Andres M, Ludwig H, Sahota SS, Zozer N. Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis. *Leukemia* (2011) **25**:1213–6. doi:10.1038/leu.2011.70
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. *Br J Haematol* (2003) **121**:749–57. doi:10.1046/j.1365-2141.2003.04355.x
- Blade J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. *Br J Haematol* (1992) **81**:391–4. doi:10.1111/j.1365-2141.1992.tb08245.x
- Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. *J Exp Med* (2003) **197**:1667–76. doi:10.1084/jem.20021650
- Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. *J Exp Med* (2003) **198**:1753–7. doi:10.1084/jem.20031030
- Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. *J Exp Med* (2007) **204**:831–40. doi:10.1084/jem.20062387
- Perez-Andres M, Santiago M, Almeida J, Mateo G, Porwit-MacDonald A, Bjorklund E, et al. Immunophenotypic approach to the identification and characterization of clonal plasma cells from patients with monoclonal gammopathies. *J Biol Regul Homeost Agents* (2004) **18**:392–8.
- Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. *N Engl J Med* (2007) **356**:2582–90. doi:10.1056/NEJMoa070389
- Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. *Blood* (2008) **111**:2516–20. doi:10.1182/blood-2007-10-116129
- Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). *Leukemia* (2009) **23**:1152–7. doi:10.1038/leu.2008.402
- Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, Blimark C, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. *Haematologica* (2012) **97**:854–854. doi:10.3324/haematol.2011.054015
- Kristinsson SY, Bjorkholm M, Andersson TM, Eloranta S, Dickman PW, Goldin LR, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. *Haematologica* (2009) **94**:1714–20. doi:10.3324/haematol.2009.010066
- Karlsson J, Andreasson B, Kondori N, Erman E, Riesbeck K, Hogevis H, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. *Clin Vaccine Immunol* (2011) **18**:969–77. doi:10.1128/CVI.00021-11

23. Mills K, Cawley J. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. *Br J Haematol* (1983) **53**:271–5. doi:10.1111/j.1365-2141.1983.tb02021.x
24. Saba H, Hartmann R, Herion J. *Hemophilus influenzae* septicemia and polyarthritis in multiple myeloma. *South Med J* (1979) **72**:743–6.
25. Schutt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Muller S, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. *Leuk Lymphoma* (2006) **47**:1570–82. doi:10.1080/10428190500472503
26. Augustsson B, Begum G, Dunn J, Barth N, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working Party. *J Clin Oncol* (2005) **23**:9219–26. doi:10.1200/JCO.2005.03.2086
27. Savage D, Lindenbaum J, Garrett T. Biphasic pattern of bacterial infection in multiple myeloma. *Ann Intern Med* (1982) **96**:47–50. doi:10.7326/0003-4819-96-1-47
28. Shaikh B, Lombard R, Appelbaum P, Bentz M. Changing patterns of infections in patients with multiple myeloma. *Oncology* (1982) **39**:78–82. doi:10.1159/000225611
29. Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. *Q J Med* (1991) **79**:517–25.
30. Jacobson D, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. *Semin Oncol* (1986) **13**:282–90.
31. Palumbo A, Dimopoulos M, San Miguel J, Harousseau J, Attal M, Hussein M, et al. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. *Blood Rev* (2009) **23**:87–93. doi:10.1016/j.blre.2008.07.003
32. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. *Am J Hematol* (2012) **87**:78–88. doi:10.1002/ajh.22237
33. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. *Lancet* (2006) **367**:825–31. doi:10.1016/S0140-6736(06)68338-4
34. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. *Clin Infect Dis* (2009) **49**:1211–4. doi:10.1086/605664
35. Chanan-Khan A, Sonneveld P, Schuster M, Stadtmauer E, Facon T, Harousseau J, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. *J Clin Oncol* (2008) **26**:4784–6. doi:10.1200/JCO.2007.14.9641
36. Cesana C, Nosari AM, Klersy C, Miqueleiz S, Rossi V, Ferrando P, et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. *Haematologica* (2003) **88**:1022–8.
37. Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP, Kovacs MJ, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. *Br J Haematol* (2007) **136**:203–11. doi:10.1111/j.1365-2141.2006.06405.x
38. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. *Lancet Oncol* (2010) **11**:29–37. doi:10.1016/S1470-2045(09)70284-0
39. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. *Leukemia* (2006) **20**:1130–7. doi:10.1038/sj.leu.2404226
40. Bohnhorst J, Rasmussen T, Moen S, Fløttum M, Knudsen L, Børset M, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. *Leukemia* (2006) **20**:1138–44. doi:10.1038/sj.leu.2404225
41. Harwood NE, Batista FD. Early events in B cell activation. *Annu Rev Immunol* (2010) **28**:185–210. doi:10.1146/annurev-immunol-030409-101216
42. Deenick EK, Ma CS, Brink R, Tangye SG. Regulation of T follicular helper cell formation and function by antigen presenting cells. *Curr Opin Immunol* (2011) **23**:111–8. doi:10.1016/j.coi.2010.10.007
43. Frasca D, Landin AM, Riley RL, Blomberg BB. Mechanisms for decreased function of B cells in aged mice and humans. *J Immunol* (2008) **180**:2741–6. doi:10.4049/jimmunol.180.5.2741
44. Wikby A, Johansson B, Ferguson F, Olsson J. Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study. *Exp Gerontol* (1994) **29**:531–41. doi:10.1016/0531-5565(94)90036-1
45. Olsson J, Wikby A, Johansson B, Löfgren S, Nilsson B, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. *Mech Ageing Dev* (2001) **121**:187–201. doi:10.1016/S0047-6374(00)00210-4
46. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. *Nat Rev Immunol* (2009) **9**:185–94. doi:10.1038/nri2508
47. Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. *J Immunol* (2005) **175**:3262–7. doi:10.4049/jimmunol.175.5.3262
48. Colonna-Romano G, Bulati M, Aquino A, Pellicanò M, Vitello S, Lio D, et al. A double-negative (IgD- CD27) B cell population is increased in the peripheral blood of elderly people. *Mech Ageing Dev* (2009) **130**:681–90. doi:10.1016/j.mad.2009.08.003
49. Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138 plasma cells. *Haematologica* (2010) **95**:1016–20. doi:10.3324/haematol.2009.018689
50. Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c B-cell population is important for the development of autoimmunity. *Blood* (2011) **118**:1305–15. doi:10.1182/blood-2011-01-331462
51. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter H, et al. Human immunoglobulin M memory B cells controlling *Streptococcus pneumoniae* infections are generated in the spleen. *J Exp Med* (2003) **197**:939–45. doi:10.1084/jem.20022020
52. Frasca D, Blomberg BB. Aging affects human B cell responses. *J Clin Immunol* (2011) **31**:430–5. doi:10.1007/s10875-010-9501-7
53. Ademokun A, Wu YC, Martin V, Mitra R, Sack U, Baxendale H, et al. Vaccination-induced changes in human B-cell repertoire and pneumococcal IgM and IgA antibody at different ages. *Ageing Cell* (2011) **10**:922–30. doi:10.1111/j.1474-9726.2011.00732.x
54. Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E, et al. B-cell diversity decreases in old age and is correlated with poor health status. *Ageing Cell* (2009) **8**:18–25. doi:10.1111/j.1474-9726.2008.00443.x
55. Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, Dran S, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. *Exp Gerontol* (2002) **37**:427–39. doi:10.1016/S0531-5565(01)00210-8
56. Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko DM. Immune response to influenza vaccination in a large healthy elderly population. *Vaccine* (1999) **17**:82–94. doi:10.1016/S0264-410X(98)00117-0
57. Beyer WE, Palache AM, Baljet M, Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. *Vaccine* (1989) **7**:385–94. doi:10.1016/0264-410X(89)90150-3
58. Iorio AM, Rivosecchia P, Zeia T, Neria M, Merletti L. Immune response to trivalent inactivated influenza vaccine in young and elderly subjects. *Vaccine* (1989) **7**:341–4. doi:10.1016/0264-410X(89)90198-9
59. Demicheli V, Di Pietrantonj C, Jefferson T, Rivetti A, Rivetti D. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev* (2007) **2**:CD001269. doi:10.1002/14651858.CD001269.pub3
60. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. *JAMA* (1994) **272**:1661–5. doi:10.1001/jama.272.21.1661
61. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. *Vaccine* (2006) **24**:1159–69. doi:10.1016/j.vaccine.2005.08.105

62. Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. *J Clin Invest* (2011) **121**:3109–19. doi:10.1172/JCI57834
63. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. *J Infect Dis* (1992) **165**(Suppl 1):S49–52. doi:10.1093/infdis/165-Supplement\_1-S49
64. Käyhty H, Karanko V, Peltola H, Mäkelä P. Serum antibodies after vaccination with *Haemophilus influenzae* type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. *Pediatrics* (1984) **24**:857–8.
65. Chu C, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of *Haemophilus influenzae* type b and pneumococcal type 6A polysaccharide-protein conjugates. *Infect Immun* (1983) **40**:245–56.
66. Granoff DM, Rathore MH, Holmes SJ, Granoff PD, Lucas AH. Effect of immunity to the carrier protein on antibody responses to *Haemophilus influenzae* type b conjugate vaccines. *Vaccine* (1993) **11**:S46–51. doi:10.1016/0264-410X(93)90160-Y
67. Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. *Infect Immun* (1999) **67**:5979–84.
68. Rubins JB, Puri AK, Loch J, Charboneau D, MacDonald R, Opstad N, et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. *J Infect Dis* (1998) **178**:431–40. doi:10.1086/515644
69. Christenson B, Lundbergh P, Hedlund J, Örtqvist Å. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. *Lancet* (2001) **357**:1008–11. doi:10.1016/S0140-6736(00)04237-9
70. Vila-Córcoles A, Ochoa-Gondar O, Ansa X, Vilanova A, Rodríguez T, Llor C. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. *Clin Infect Dis* (2006) **43**:860–8. doi:10.1086/507340
71. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. *Lancet* (2005) **366**:1165–74. doi:10.1016/S0140-6736(05)67339-4
72. Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, et al. Antibody responses to nasopharyngeal carriage of *Streptococcus pneumoniae* in adults: a longitudinal household study. *J Infect Dis* (2005) **192**:387–93. doi:10.1086/431524
73. Simell B, Lahdenkari M, Reunanen A, Käyhty H, Väkeväinen M. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. *Clin Vaccine Immunol* (2008) **15**:1391–7. doi:10.1128/0140-6736(05)67339-4
74. Koivula M, Stén M, Leinonen M, Mäkelä M, Helena P. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. *Am J Med* (1997) **103**:281–90. doi:10.1016/S0002-9343(97)00149-6
75. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Läärä E, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. *Vaccine* (1999) **17**:2493–500. doi:10.1016/S0264-410X(99)00069-9
76. Kelly DF, Moxon ER, Pollard AJ. *Haemophilus influenzae* type b conjugate vaccines. *Immunology* (2004) **113**:163–74. doi:10.1111/j.1365-2567.2004.01971.x
77. Käyhty H. Difficulties in establishing a serological correlate of protection after immunization with *Haemophilus influenzae* conjugate vaccines. *Biologicals* (1994) **22**:397–402. doi:10.1006/biol.1994.1062
78. Lucas AH, Reason DC. Aging and the immune response to the *Haemophilus influenzae* type b capsular polysaccharide: retention of the dominant idiotype and antibody function in the elderly. *Infect Immun* (1998) **66**:1752–4.
79. Kantor E, Luxenberg JS, Lucas AH, Granoff DM. Phase I study of the immunogenicity and safety of conjugated *Haemophilus influenzae* type b vaccines in the elderly. *Vaccine* (1997) **15**:129–32. doi:10.1016/S0264-410X(96)00164-8
80. Ghia P, Prato G, Scielzo C, Stella S, Geuna M, Guida G, et al. Monoclonal CD5 and CD5-B-lymphocyte expansions are frequent in the peripheral blood of the elderly. *Blood* (2004) **103**:2337–42. doi:10.1182/blood-2003-09-3277
81. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. *Blood* (2002) **100**:3095–100. doi:10.1182/blood-2001-12-0297
82. Hijmans W, Radil J, Bottazzo GF, Doniach D. Autoantibodies in highly aged humans. *Mech Ageing Dev* (1984) **26**:83–9. doi:10.1016/0047-6374(84)90167-2
83. Nikolic-Zugich J. T cell aging naive but not young. *J Exp Med* (2005) **201**:837–40. doi:10.1084/jem.20050341
84. Lee N, Shin MS, Kang I. T-cell biology in aging, with a focus on lung disease. *J Gerontol A Biol Sci Med Sci* (2012) **67**:254–63. doi:10.1093/gerona/glr237
85. Henson SM, Akbar AN. Memory T-cell homeostasis and senescence during aging. *Memory T Cells Anonymous*. New York: Springer (2010). p. 189–97.
86. Gregersen H, Madsen KM, Sorensen HT, Schonheyder HC, Ibsen JS, Dahlerup JF. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. *Eur J Haematol* (1998) **61**:140–4. doi:10.1111/j.1600-0609.1998.tb01075.x
87. Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sorensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. *Haematologica* (2001) **86**:1172–9.
88. Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. *Blood* (1996) **87**:912–8.
89. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. *J Clin Oncol* (2002) **20**:1625–34. doi:10.1200/JCO.20.6.1625
90. Kyrtonis MC, Mouzaki A, Maniatis A. Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM). *Med Oncol* (1999) **16**:73–7. doi:10.1007/BF02785839
91. Perez-Persona E, Mateo G, Garcia-Sanz R, Mateos MV, de Las Heras N, de Coca AG, et al. Risk of progression in smoldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. *Br J Haematol* (2010) **148**:110–4. doi:10.1111/j.1365-2141.2009.07929.x
92. Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ III, et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. *Leukemia* (2013) **27**:208–12. doi:10.1038/leu.2012.189
93. Tete SM, Wilting KR, Horst G, Klijn MA, Westra J, de Haan A, et al. IgG antibody and TH1 immune responses to influenza vaccination negatively correlate with M-protein burden in monoclonal gammopathy of undetermined significance. *Hematol Leuk* (2013) **1**:3. doi:10.7243/2052-434X-1-3
94. Harrison SJ, Franklin IM, Campbell JD. Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy. *Leuk Lymphoma* (2008) **49**:2272–83. doi:10.1080/10428190802464729
95. Pessoa de Magalhães R, Vidriales M, Paiva B, Fernandez-Gimenez C, García-Sanz R, Mateos M, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. *Haematologica* (2013) **98**:79–86. doi:10.3324/haematol.2012.067272
96. Olteanu H, Wang HY, Chen W, McKenna RW, Karandikar NJ. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. *BMC Clin Pathol* (2008) **8**:13. doi:10.1186/1472-6890-8-13
97. de Tute RM, Jack AS, Child JA, Morgan GJ, Owen RG, Rawstron AC. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. *Leukemia* (2007) **21**:2046–9. doi:10.1038/sj.leu.2404815
98. Marsee DK, Li B, Dorfman DM. Single tube, six-color flow cytometric analysis is a sensitive and cost-effective technique for assaying clonal plasma cells. *Am J Clin Pathol* (2010) **133**:694–9. doi:10.1309/AJCPKKNPMLWX9ZXB
99. Kobayashi S, Hyo R, Amitani Y, Tanaka M, Hashimoto C, Sakai R, et al. Four-color flow cytometric analysis of myeloma plasma cells. *Am J Clin Pathol* (2006) **126**:908–15. doi:10.1309/VWXARAAG9DAPQ31Y
100. Paiva B, Pérez-Andrés M, Vidriales M, Almeida J, de Las Heras N, Mateos M, et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs. myeloma. *Leukemia* (2011) **25**:697–706. doi:10.1038/leu.2010.320
101. Kovarova L, Buresova I, Buchler T, Suska R, Pour L, Zahradova L, et al. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy

- of undetermined significance. *Neoplasia* (2009) **56**:526–32. doi:10.4149/neo\_2009\_06\_526
102. Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. *J Clin Oncol* (2005) **23**:5668–74. doi:10.1200/JCO.2005.03.159
  103. Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR, et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. *Blood* (1996) **88**:289–96.
  104. Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. *Br J Haematol* (1997) **97**:46–55. doi:10.1046/j.1365-2141.1997.72653.x
  105. Ocqueteau M, Orfao A, Almeida J, Bladé J, Gonzalez M, García-Sanz R, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. *Am J Pathol* (1998) **152**:1655.
  106. Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. *Blood* (2005) **106**:2276–9. doi:10.1182/blood-2005-05-1858
  107. Witzig T, Gertz M, Lust J, Kyle R, O'Fallon W, Greipp P. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. *Blood* (1996) **88**:1780–7.
  108. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med* (2002) **346**:564–9. doi:10.1056/NEJMoa01133202
  109. Raitakari M, Brown RD, Gibson J, Joshua DE. T cells in myeloma. *Hematol Oncol* (2003) **21**:33–42. doi:10.1002/hon.704
  110. Murakami H, Ogawara H, Hiroshi H. Th1/Th2 cells in patients with multiple myeloma. *Hematology* (2004) **9**:41–5. doi:10.1080/10245330310001652437
  111. Cousins D, Lee T, Staynov D. Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines. *J Immunol* (2002) **169**:2498–506. doi:10.4049/jimmunol.169.5.2498
  112. Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. *Genes Dev* (2000) **14**:1693–711. doi:10.1101/gad.14.14.1693
  113. Zhang XL, Komada Y, Chipeta J, Li QS, Inaba H, Azuma E, et al. Intracellular cytokine profile of T cells from children with acute lymphoblastic leukemia. *Cancer Immunol Immunother* (2000) **49**:165–72. doi:10.1007/s002620050616
  114. Mori T, Takada R, Watanabe R, Okamoto S, Ikeda Y. T-helper (Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma. *Cancer Immunol Immunother* (2001) **50**:566–8. doi:10.1007/s00262-001-0232-8
  115. Frassanito M, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. *Clin Exp Immunol* (2001) **125**:190–7. doi:10.1046/j.1365-2249.2001.01582.x
  116. Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, et al. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. *Br J Haematol* (2003) **121**:842–8. doi:10.1046/j.1365-2141.2003.04375.x
  117. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. *Nat Med* (2004) **10**:801–5. doi:10.1038/nm0804-801
  118. Buckner JH, Ziegler SE. Regulating the immune system: the induction of regulatory T cells in the periphery. *Arthritis Res Ther* (2004) **6**:215–24. doi:10.1186/ar1226
  119. Bacchetta R, Gregori S, Roncarolo M. CD4 regulatory T cells: mechanisms of induction and effector function. *Autoimmun Rev* (2005) **4**:491–6. doi:10.1016/j.autrev.2005.04.005
  120. Niederkorn JY. Emerging concepts in CD8 T regulatory cells. *Curr Opin Immunol* (2008) **20**:327–31. doi:10.1016/j.coi.2008.02.003
  121. Thomson CW, Lee BP, Zhang L. Double-negative regulatory T cells. *Immunol Res* (2006) **35**:163–77. doi:10.1385/IR:35:1:163
  122. Romagnani S. Regulation of the T cell response. *Clin Exp Allergy* (2006) **36**:1357–66. doi:10.1111/j.1365-2222.2006.02606.x
  123. Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4 CD25 regulatory T cells. *J Immunol* (2004) **172**:5986–93. doi:10.4049/jimmunol.172.10.5986
  124. Prabhala R, Neri P, Bae J, Tassone P, Shammass M, Allam C, et al. Dysfunctional T regulatory cells in multiple myeloma. *Blood* (2006) **107**:301–4.
  125. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch M, Knolle P, et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. *Blood* (2006) **107**:3940–9. doi:10.1182/blood-2005-09-3671
  126. Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft A, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(–)CD8(–)alpha-betaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. *Br J Haematol* (2009) **144**:686–95. doi:10.1111/j.1365-2141.2008.07530.x
  127. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. *Br J Cancer* (2012) **106**:546–52. doi:10.1038/bjc.2011.575
  128. Sakaguchi S, Setoguchi R, Yagi H, Nomura T. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease. *Curr Top Microbiol Immunol* (2006) **305**:51–66.
  129. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. *Blood* (2002) **100**:230–7. doi:10.1182/blood.V100.1.230
  130. Brimnes MK, Svane IM, Johnsen HE. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. *Clin Exp Immunol* (2006) **144**:76–84. doi:10.1111/j.1365-2249.2006.03037.x
  131. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. *Blood* (2001) **98**:2992–8. doi:10.1182/blood.V98.10.2992
  132. Brown R, Murray A, Pope B, Sze DM, Gibson J, Ho PJ, et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. *Br J Haematol* (2004) **125**:743–8. doi:10.1111/j.1365-2141.2004.04984.x
  133. Straube C, Wehner R, Wendisch M, Bornhauser M, Bachmann M, Rieber EP, et al. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. *Leukemia* (2007) **21**:1464–71. doi:10.1038/sj.leu.2404734
  134. Nencioni A, Garuti A, Schwarzenberg K, Cirmena G, Dal Bello G, Rocco I, et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. *Eur J Immunol* (2006) **36**:681–9. doi:10.1002/eji.200535298
  135. Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. *Cancer Cell* (2009) **16**:309–23. doi:10.1016/j.ccr.2009.08.019
  136. Bae J, Prabhala R, Munshi NC. Dendritic cells and peptide-based vaccine in multiple myeloma. In: Munshi N, Anderson K, editors. *Advances in Biology and Therapy of Multiple Myeloma*. New York: Springer (2013). p. 131–54.
  137. Schultze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response. *Blood Rev* (1996) **10**:111–27. doi:10.1016/S0268-960X(96)90040-5
  138. Draghi M, Pashine A, Sanjanwala B, Gendzekhadze K, Cantoni C, Cosman D, et al. NKP46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. *J Immunol* (2007) **178**:2688–98. doi:10.4049/jimmunol.178.5.2688
  139. Bhardwaj N, Bender A, Gonzalez N, Bui LK, Garrett MC, Steinman RM. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8 T cells. *J Clin Invest* (1994) **94**:797. doi:10.1172/JCI117399
  140. Garcia-Sanz R, Gonzalez M, Orfao A, Moro MJ, Hernandez JM, Borrego D, et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. *Br J Haematol* (1996) **93**:81–8. doi:10.1046/j.1365-2141.1996.4651006.x



141. Osterborg A, Nilsson B, Bjorkholm M, Holm G, Mellstedt H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. *Eur J Haematol* (1990) **45**:153–7. doi:10.1111/j.1600-0609.1990.tb00443.x
142. Gonzalez M, San Miguel JF, Gascon A, Moro MJ, Hernandez JM, Ortega F, et al. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. *Am J Hematol* (1992) **39**:84–9. doi:10.1002/ajh.2830390203
143. Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. *Med Oncol* (2007) **24**:312–7. doi:10.1016/S0145-2126(07)70390-9
144. Costello RT, Boehrer A, Sanchez C, Mercier D, Baier C, Le Treut T, et al. Differential expression of natural killer cell activating receptors in blood vs. bone marrow in patients with monoclonal gammopathy. *Immunology* (2013) **139**:338–41. doi:10.1111/imm.12082
145. Carbone E, Neri P, Mesuraca M, Fulciniti M, Otsuki T, Pende D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. *Blood* (2005) **105**:251–8. doi:10.1182/blood-2004-04-1422
146. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. *Proc Natl Acad Sci U S A* (2008) **105**:1285–90. doi:10.1073/pnas.0711293105
147. von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, et al. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. *Cancer Immunol Immunother* (2010) **59**:829–39. doi:10.1007/s00262-009-0807-3
148. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. *Blood* (2001) **98**:210–6. doi:10.1182/blood.V98.1.210
149. Jungkunz-Stier I, Zekla M, Stuhmer T, Einsele H, Seggewiss Bernhard R. Modulation of NK cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells. *Leuk Lymphoma* (2014) **55**:168–76. doi:10.3109/10428194.2013.794270
150. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. *Br J Haematol* (2007) **138**:563–79. doi:10.1111/j.1365-2141.2007.06705.x
151. Campbell JD, Cook G, Robertson SE, Fraser A, Boyd KS, Gracie JA, et al. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. *J Immunol* (2001) **167**:553–61. doi:10.4049/jimmunol.167.1.553
152. Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. *Blood* (2000) **95**:2630–6.
153. Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, Rosato R, et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. *Blood* (2005) **105**:4784–91. doi:10.1182/blood-2004-11-4201
154. Gross P, Hermogenes A, Sacks H, Lau J, Levandowski R. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. *Ann Intern Med* (1995) **123**:518–27. doi:10.7326/0003-4819-123-7-199510010-00008
155. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. *Br Med Bull* (1979) **35**:69–75.
156. Robertson J, Nagesh K, Jowitt S, Dougal M, Anderson H, Mutton K, et al. Immunogenicity of vaccination against influenza, *Streptococcus pneumoniae* and *Haemophilus influenzae* type B in patients with multiple myeloma. *Br J Cancer* (2000) **82**:1261–5. doi:10.1054/bjoc.1999.1088
157. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. *Br J Haematol* (2005) **130**:96–8. doi:10.1111/j.1365-2141.2005.05582.x
158. Kroon F, van Dissel J, de Jong J, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. *AIDS* (1994) **8**:469–76.
159. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciú H, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. *Bone Marrow Transplant* (1993) **11**:1–5.
160. Rapezzi D, Sticchi L, Racchi O, Mangerini R, Ferraris AM, Gaetani GF. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. *Eur J Haematol* (2003) **70**:225–30. doi:10.1034/j.1600-0609.2003.00028.x
161. Schiffman G, Douglas RM, Bonner MJ, Robbins M, Austrian R. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. *J Immunol Methods* (1980) **33**:133–44. doi:10.1016/S0022-1759(80)80004-4
162. Landesman S, Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. *Rev Infect Dis* (1981) **3**(Suppl):S184–97. doi:10.1093/clinids/3.Supplement\_1.S184
163. Schmid GP, Smith RP, Baltch AL, Hall CA, Schiffman G. Antibody response to pneumococcal vaccine in patients with multiple myeloma. *J Infect Dis* (1981) **143**:590–7. doi:10.1093/infdis/143.4.590
164. Birgens H, Espersen F, Hertz J, Pedersen F, Drivsholm A. Antibody response to pneumococcal vaccination in patients with myelomatosis. *Scand J Haematol* (1983) **30**:324–30. doi:10.1111/j.1600-0609.1983.tb01500.x
165. Lazarus HM, Lederman M, Lubin A, Herzig RH, Schiffman G, Jones P, et al. Pneumococcal vaccination: the response of patients with multiple myeloma. *Am J Med* (1980) **69**:419–23. doi:10.1016/0002-9343(80)90014-5
166. Hargreaves R, Lea J, Griffiths H, Faux J, Holt J, Reid C, et al. Immunological factors and risk of infection in plateau phase myeloma. *J Clin Pathol* (1995) **48**:260–6. doi:10.1136/jcp.48.3.260
167. Nix EB, Hawdon N, Gravelle S, Biman B, Brigden M, Malik S, et al. Risk of invasive *Haemophilus influenzae* type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era. *Clin Vaccine Immunol* (2012) **19**:766–71. doi:10.1128/CVI.05675-11
168. Small TN, Keever CA, Weiner-Fedus S, Heller G, O'Reilly RJ, Flomenberg N. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. *Blood* (1990) **76**:1647–56.
169. Storek J, Saxon A. Reconstitution of B cell immunity following bone marrow transplantation. *Bone Marrow Transplant* (1992) **9**:395–408.
170. Witherspoon RP, Lum LG, Storb R. Immunologic reconstitution after human marrow grafting. *Semin Hematol* (1984) **21**:2–10.
171. Fox R, McMillan R, Spruce W, Tani P, Mason D. Analysis of T lymphocytes after bone marrow transplantation using monoclonal antibodies. *Blood* (1982) **60**:578–82.
172. Ault KA, Antin JH, Ginsburg D, Orkin SH, Rapoport JM, Keohan ML, et al. Phenotype of recovering lymphoid cell populations after marrow transplantation. *J Exp Med* (1985) **161**:1483–502. doi:10.1084/jem.161.6.1483
173. Gandhi MK, Egner W, Sizer L, Inman I, Zambon M, Craig JJ, et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. *Bone Marrow Transplant* (2001) **28**:775–81. doi:10.1038/sj.bmt.1703239
174. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. *Transplantation* (2008) **86**:257–63. doi:10.1097/TP.0b013e3181772a75
175. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. *Bone Marrow Transplant* (2008) **42**:637–41. doi:10.1038/bmt.2008.264
176. Ljungman P. Immunization of transplant recipients. *Bone Marrow Transplant* (1999) **23**:635–6. doi:10.1038/sj.bmt.1701641
177. Hinge M, Ingels HA, Slotved HC, Molle I. Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. *APMIS* (2012) **120**:935–40. doi:10.1111/j.1600-0463.2012.02922.x
178. Lortan JE, Vellodi A, Jorges ES, Hugh-Jones K. Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation. *Clin Exp Immunol* (1992) **88**:512–9. doi:10.1111/j.1365-2249.1992.tb06480.x
179. Parkkali T, Kayhty H, Ruutu T, Volin L, Eskola J, Ruutu P. A comparison of early and late vaccination with *Haemophilus influenzae* type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. *Bone Marrow Transplant* (1996) **18**:961–7.

180. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. *Nat Med* (2005) **11**:1230–7. doi:10.1038/nm1310
181. Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. *Blood* (2011) **117**:63–71. doi:10.1182/blood-2010-07-296822

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 25 February 2014; accepted: 18 May 2014; published online: 03 June 2014.

Citation: Tete SM, Bijl M, Sahota SS and Bos NA (2014) Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. *Front. Immunol.* **5**:257. doi: 10.3389/fimmu.2014.00257

This article was submitted to *B Cell Biology*, a section of the journal *Frontiers in Immunology*.

Copyright © 2014 Tete, Bijl, Sahota and Bos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.